Tarsus Pharmaceuticals (TARS) Non Operating Investment Income (2023 - 2024)

Tarsus Pharmaceuticals' (TARS) quarterly Non Operating Investment Income came in at -$6000.0 in Q2 2024, down 140.0% year-on-year from $15000.0 in Q3 2023, and down 101.43% quarter-over-quarter from $420000.0 in Q4 2023.

Tarsus Pharmaceuticals (TARS) Non Operating Investment Income (2023 - 2024) Analysis & Trends

Tarsus Pharmaceuticals' Non Operating Investment Income history runs 2 years deep, the most recent figure standing at -$6000.0 for Q2 2024.

  • On a quarterly basis, Non Operating Investment Income fell 140.0% year-over-year to -$6000.0 in Q2 2024; TTM through Dec 2024 was $414000.0, a N/A change from a year earlier, with the FY2024 full-year figure at -$591000.0, down 328.19% from the prior year.
  • Non Operating Investment Income declined to -$6000.0 in Q2 2024 per TARS's latest filing, from $420000.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $420000.0 in Q4 2023 and bottomed at -$111000.0 in Q3 2023.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Oculis Holding AG 66,831.58 Bn 66,831.30 Bn - -
2 Nanobiotix 1,916.61 Bn 1,916.55 Bn - -
3 Akari Therapeutics 976.78 Bn 976.78 Bn - -
4 BeOne Medicines 471.48 Bn 466.69 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.78 Bn 114.53 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 69.87 Bn 61.12 Bn 3.31 Bn -
7 Belite Bio 63.06 Bn 63.06 Bn - -
8 Argenx Se 55.78 Bn 50.60 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.54 Bn 34.53 Bn 959.66 Mn -
10 Tarsus Pharmaceuticals 2.60 Bn 2.50 Bn 152.66 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2024 -6,000.00
Jun 30, 2024 -6,000.00
Dec 31, 2023 420,000.00
Dec 31, 2023 420,000.00
Sep 30, 2023 -111,000.00
Sep 30, 2023 -111,000.00
Jun 30, 2023 15,000.00
Jun 30, 2023 15,000.00